Kevin Eggan

Kevin Eggan began their work experience in 2003 at Harvard University as a Harvard Junior Fellow and later became an Assistant Professor, Associate Professor, and ultimately a Professor. In 2004, they also joined the Harvard Stem Cell Institute as a Principal Investigator. In 2009, they became a member of the Scientific Advisory Board (SAB) at Ipierian. In 2013, they founded Q-State Biosciences and in 2017 founded QurAlis. In 2018, they founded EnClear Therapies. Kevin'smost recent role is as the CSO/Head of Research and Early Development at BioMarin Pharmaceutical Inc., which they started in October 2020.

Kevin Eggan completed their Bachelor of Science degree in Microbiology and Immunology at the University of Illinois Urbana-Champaign from 1992 to 1996. Kevin then pursued their Ph.D. in Biology at the Massachusetts Institute of Technology from 1998 to 2003.